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A B S T R A C T
The aim of the paper was to evaluate current emergency contraception (EC) methods and policies in order to imple-
ment lessons learned and maximize potential population impact while introducing dedicated EC pills in Croatia. Litera-
ture search for potential reasons for EC failing to show positive population impact and detecting actionable points to be
implemented in national guidelines. Six potential reasons for ECs failure to show population impact were evaluated and
four actionable points were detected: low use of EC compared to the numbers of risk events, low awarenes on EC in gen-
eral populaton, differences in efficacy of EC methods and EC vailability. In order to ensure EC’s population impact in
Croatia it is of a critical relevance to establish continuous education programs for population of women at risk. When
recommending an EC method, superior efficacy must be a key decison-making criteria therefore cooper IUD and uli-
pristal acetate should be our primary options. Counseling is a critical step to ensure maximal efficacy of the EC method,
but also to encourage future use of regular contraceptives. Finally, national ECP dispension protocol is needed to close
the loop from effective women screening, prompt yet appropriate ECP administration/dispensing towards structured fol-
low up after EC pills intake.
Key words: emergency contraception, population impact of emergency contraception, emergency contraception effi-
cacy, providing emergency contraception pills
Introduction
Emergency contraceptives are methods women can
use after intercourse to prevent pregnancy1. Up to the
very recent past, there was no dedicated emergency con-
traception pill (ECP) in Croatia: a single 1.500mcg levo-
norgestrel pill was introduced only in 2010, 10 years af-
ter its introduction in Europe2. It was shortly followed by
a single 30mg ulipristal pill3, quickly up on its registra-
tion in EU and US. Current ECP options in Croatia re-
sembles US, however both products are prescription
products in Croatia, while levonorgestrel pill (LNG) has
»over the counter« status in US. In some other countries
combined pills (containing ethinilestradiol and levonor-
gestrel or norgestrel), often called Yuzpe regimen, are
also available.
Combined EC pills were withdrawn from the US mar-
ket in 2004, due to the availability of safer and more ef-
fective emergency contraceptives4. Although in Croatia
there was never a dedicated and registered Yuzpe pill,
the method is most probably still in use (usingregular
COCs available) due to the late introduction of levonor-
gestrel in the market. In China, Vietnam and Russia
mifepristone is also available as ECP, but in the most EU
markets it is used as an chemical abortificant only4,5.
Similar to the case in US, mifepristone is unavailable in
Croatia. In despite of wide availability of contraceptive
methods, including ECPs, close to 50% of pregnancies
are still unplanned, and 25%of those are artificially ter-
minated6,7.
Almost 2 decades ago an objective for EC has been set
by Trussel et al., aiming for widespread use of ECPs to
prevent half of all unintended pregnancies and abortions
in the US each year8. Regrettably, none of the eleven
published studies – 9 randomized trials and 1 cohort
study enrolling altogether 11.830 women – has demon-
strated that increasing access to ECPs reduces preg-
nancy or abortion rates at population levels9,10. One dem-
onstration project (ECPs were given to 17.831 women)11
and three clinical trials12–14 were designed to address this
issue.
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In despite of several flaws in studies, consistency in
the findings can hardly be ignored: increased access to
EC did not have any impact in terms of reducing non-in-
tended pregnancy rates9–14. Since the number of legally
introduced abortions in Croatia is high (10.616 in 2008),
from Croatian national perspective it is important and
practically relevant to evaluate current EC methods and
policies in order to implement lessons learned and maxi-
mize potential population impact while still introducing
dedicated ECPs in Croatia15.
Methods
Literature search has been executed to establish pop-
ulation impacts of emergency contraception and further
more to detect and evaluate potential reasons for method
failing to show any substantial population benefits. Six
potential reasons were further evaluated: flaws in stud-
ies addressing the topic, possible increased risk taking
related to the availability of ECP, low ECP usage rates
compared to risk event rates, low ECP awareness in gen-
eral population, problems with ECPs efficacy, and ECP
availability. Four actionable points were detected and
recommendations for action were drawn based on the lit-
erature findings.
Results and Discussion
In searching for action points, several possible expla-
nations for ECPs failing to show population impact were
detected and evaluated.
Problems with the studies
Eleven studies were conducted in 4 countries during
the period from 1998–2006. Yuzpe pills, levonorgestrel
and mifepistrone (in China study only) were provided as
emergency contraception method. Total of 11.830 women
were enrolled in 9 comparative trials and one cohort
study. Additional 17.831 women were given ECPs in ad-
vance as a part of demonstration project11. Women were
followed up to one year, and pregnancy rates were com-
pared between the two groups: group with increased ac-
cess compared to the group with standard access. Consis-
tently, no difference has been demonstrated between the
groups, failing to demonstrate ECP’s benefits at popula-
tion level. Several problems with the studies could be
highlighted: small size (ranging from 160–2.686 women),
substantial loss to follow up (ranging from 1–62%), mod-
erate intervention, sound access in the control group,
lack of randomization, low baseline risk of pregnancy9–14.
However, none of the studies had all flaws, and 3 studies
and 1 project were designated particularly for the pur-
pose. In this context, consistency in findings out wages
each particular study flaws, therefore it seems hard to at-
tribute lack of ECPs population impact to the flaws in
study designs.
Increased risk taking related to the availability of
ECP
Fifteen studies have demonstrated that making ECPs
more widely available did not increase sexual risk ta-
king11–14,16–27. In addition, four studies further demon-
strated no impact of easier access of ECPs on rates of sex-
ually transmitted diseases and incidence of STD12,14,21,26.
One study has demonstrated that educating teens about
ECPs did increase their knowledge about proper ECP ad-
ministration; however it did not increase their level of
sexual activity28. However, one reanalysis of the random-
ized trial suggested that easier access to ECPs may have
increased the frequency of coital acts with the potential
lead to pregnancy29.
Women with increased access to ECPs in this study
were more likely to report that they had used EC because
they did not want to use another contraceptive method30.
Therefore, though there are some conflicting findings, it
is hard to attribute lack of ECPs population impact to the
increased risk taking.
ECPs are used too rarely compared to the number
of risk situations to result in a substantial
population impact
The fraction of women aged 15–44 years who had ever
used EPCs increased from 2% in 2022 to 10% in
2006–200831. Still, one trial has demonstrated that even
when provided in advance, 45% of the women who had an
unprotected intercourse did not use ECP14. In another
trial 33% of women in the advance provision group had at
least one unprotected intercourse without using ECPs32.
Furthermore, in the same trial increased access to ECPs
increased its use the most within the group of the women
who were at lower baseline risk of pregnancy32. Existing
data suggests EC underuse and may partially explain the
lack of measurable population effects from an increased
access to ECPs. Also, this represents an actionable point
that is highly related to the awareness about and avail-
ability of ECPs.
Low awareness on EC options among women
Due to the small size of the pharma companies ini-
tially distributing ECPs, those companies were not able
to promote emergency contraception products at the
same scale as most pharmaceuticals, particularly in terms
of raising population education campaigns. Furthermo-
re, even after levonorgestrel being acquired by major ge-
neric players, none of these companies made significant
investments in direct to consumer advertising and edu-
cation. Without commercial marketing and broad educa-
tional campaigns many women still do not know that
emergency contraception is available, effective and safe.
Many initiatives have been undertaken to improve awa-
reness and use of emergency contraception. In despite of
the lack of the precise population awareness data, this
observation may partially explain why we still lack mea-
surable population effects from an increased access to
ECPs, and it represents an actionable point.
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Problems with ECPs efficacy
The effectiveness of emergency contraception as a
preventive therapy is measured by comparing the chance
that the pregnancy will occur if the treatment is used to
the chance that it will occur without any treatment. Un-
like many other preventive treatments, in emergency
contraception initial efficacy was demonstrated by non
comparative observational studies as in this indication
placebo controlled study design is considered non ethical.
Therefore, ECPs efficacy estimations compare published
data on the probability of pregnancy on each day of the
menstrual cycle to the actual number of pregnancies ob-
served after treatment in observational treatment trials.
Emergency insertion of copper-releasing IUDs is more
effective than emergency contraceptive pills (ECPs) re-
ducing the risk of pregnancy following unprotected inter-
course by more than 99%: more than 12.000 post-coital
insertions of copper IUDs known resulted in 12 pregnan-
cies only33,34. Although copper IUDs act primarily to pre-
vent fertilization, such a high level of effectiveness implies
that it must prevent some pregnancies after fertilization
as well. Emergency contraceptive pills (ECPSs) prevent
pregnancy primarily by delaying or inhibiting ovulation
and inhibiting fertilization. The best available evidence
indicates that ECPs prevent pregnancy by mechanisms
that do not interfere with post-fertilization events35–38.
ECPs do not cause abortion; neither have they harmed
established pregnancy39. Their efficacy is calculated as a
ratio between observed and expected number of preg-
nancies40,41. Obviously, emergency contracpetives effec-
tiveness calculation model implies many assumptions
that are hard to validate (including timing of the inter-
course and cycle day/time of ovulation), but it is quite
clear that that providing emergency contraception is
better than doing nothing in preventing pregnancy after
unprotected intercourse42. Ulipristal acetate, a proge-
steron receptor modulator is the most effective ECP op-
tion with reported
effectiveness ranging from 62% to 85%43–45. Two ran-
domized trials compared the efficacy of levonorgestrel
and ulipristal acetate, 72 and 120 hours after inter-
course43,44. After these two studies were combined in a
meta analysis, ulipristal acetate was found to have a
pregnancy rate 42% lower than levnorogestrel up to 72h
and 65% lower in the first 24 hours43. In the second ran-
domized trial ulpiristal prevented significantly more preg-
nancies than levonorgestrel in the 72–120h subgroup43.
Key reason for superior efficacy seems to be the fact
that UPA is more effective than LNG in postponing im-
minent ovulation: LNG is no more effective than pla-
cebo in preventing ovulation when the leading follicle
reaches 15–17 mm46.
On the contrary, UPA delays ovulation for at least 5
days in 59% of cycles by the time follicle reaches 18–20
mm and when probability of conception without medica-
tion is more than 30%37. Levonorgestrel only regimen
was studied in eleven studies43,44,47–49,50–55 finding that
this regimen reduced a woman’s chance of getting preg-
nant by 52–100%. Studies have shown that a single dose
of LNG is as effective as and causes no more side effects
than taking two 750 mcg doses apart48,50.
Two randomized trials compared efficacy of levonor-
gestrel versus Yuzpe regimen, demonstrating superior
levonorgestrel efficacy52,53. A meta-analysis of eight stud-
ies of the combined regimen concluded that this regimen
prevents 74% of expected pregnancies56. However, more
recent analysis has established that this might be an
overestimation, finding effectiveness of 53% and 47% in
two of the largest trials of the combined regimen57. Fur-
thermore, combined data from two randomized trials
that directly compared levonorgestrel only to combined
regimen showed relative risk of pregnancy of 0.51, indi-
cating that the chance of pregnancy among women who
received levonorgestrel only was about half of the chance
among those who received combined regimen42,52,53. Ob-
viously this estimate only implies relative efficacies of
two regimens, while it does not assume the number of
pregnancies that would have been observed in the ab-
sence of the treatment. Several studies demonstrated
that both regimens are more effective the sooner after in-
tercourse pills are taken48,50,53,54,58–69, and the initial stud-
ies showed that these regimens are effective when used
up to 72 hours after intercourse53,61.
Later studies indicated that both regimens continue
to be moderately effective within 120 hours48,51,54,62,63 but
local regulators clearly limit their use within 72 hours2,3.
An interesting pilot study has demonstrated that adding
a COX-2 inhibitors (meloxicam 15mg) to 1.500 mcg levo-
norgestrel has increased the proportion of cycles with no
follicular rupture or with ovulatory dysfunction, and
that COX-2 inhibitors can disturb the ovulation after the
onset of the LH surge64. However, much more evidence is
needed on this interesting matter to become promising.
To ensure maximal EC efficacy, it seems relevant to un-
derline that only proper counseling prior EC taking could
secure women to understand that ECPs protect only
from the previous unprotected intercourse, while IUD
protects also from future intercourses.After evaluating
efficacy data, it is clear that copper IUD is the most effec-
tive method that is seldom implemented in emergency
contraception. The most effective ECP is ulipristal ace-
tate, while progestin only regimen is more effective com-
pared to the combined regimen. Introduction of the most
effecitve ECP ulipristal acetate whenever possible and as
soon as possible may improve total efficacy outcomes,
and it also seems reasonable to recommend providing it
to patients planned for EC IUD insertion as well4. From
the safety side, there are no evidence that ECPs cause
any long term adverse effects on woman’s fertility. Levo-
norgestrel is substantially better tolerated when com-
pared to combined ECPs53. When comparing local sum-
maries of product characteristics (SMPCs) for levonor-
gestrel and ulipristal acetate, it becomes obvious that
side effect profiles are comparable, mostly mild and mod-
erate for both products. However, unlike clinical trials
conclusions on the comparable tolerability of levonor-
gestrel and ulipristal acetate43,44, SMPCs suggests that
side effects in general occur more frequently (more than
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10%) or lower with LNG (nausea, tiredness, lower ab-
dominal pain, vaginal bleeding that is not a menstrual
bleeding) 2. Ulipristal causes the same side effects, but it
seems that they occur in category frequently (more than
15 but less than 10%) or less3. Routine administration of
the anti-nausea medication 1 hour before ECP may help
reduce nausea and vomiting65, but it is generally consid-
ered unnecessary with use of ulipristal acetate or levno-
norgestrel. It is not yet clear if it is necessary to repeat
the ECP dose if the woman vomits within 2 hours after
taking ECP as there are entirely opposite views on this
without conclusive evidence. When considering potential
ECPs’ effects on inadvertently exposed pregnancies, it is
important to note that in the case of the treatment fail-
ure, ECPs are taken long before organogenesis starts so
they should not have teratogenic effect66. A number of
studies have examined births to women who inadver-
tently continued to take COCwithout knowing they were
pregnant and have found no increased risk of birth
defects67–69. One study of 332 pregnant women who had
used levonorgestrel only ECP in the conception cycle
found no increased risk of birth defects70. Preclinical
data and pregnancy register on ulipristal acetate sug-
gests the same although the numbers are small. ECPs in-
deed should not be used in pregnancy but not because
they are harmful but because they are ineffective4.
Emergency contraception availability
Determining pregnancy risk is not always straightfor-
ward – the risk is low except 5 days before ovulation and
on the day of ovulation. Regrettably, neither woman or
clinician is likely to know on which day ovulation occurs.
As it is established that only 30% of women ovulate
within the fertile window71, any women requesting emer-
gency contraception after unprotected intercourse should
be offered treatment within 120h of intercourse48,51,62,63.
Until summer 2010 the lack of a product specifically
packaged, labeled and marketed as an emergency contra-
ceptive was a major obstacle to more widespread use of
emergency contraception in Croatia. In mid 2010 levo-
norgestrel (Escapelle) was brought into market, and
shortly afterwards in December 2010 ulipristal acetate
(ellaOne) has been approved. Both products are prescrip-
tion only products in Croatia, and both products are not
reimbursed, therefore both are paid by the user. Both
products fall into the same price range for the end user
(25_0length and 29_0length respectively), both being significantly more
expensive compared to combined contraceptives that were
previously used off label for this indication.
While ulipristal acetate (due to its recent introduction
in 2009) is prescription product, levonorgestrel has been
available over the counter with or without restrictions in
many countries. However in most countries it is still not
available on the shelf but it is kept behind the pharmacy
counter, and its use is limited by pharmacist’s will to dis-
pense EPC, but also by woman’s embarrasses to ask for
an ECP. OTC as a solution has another negative out-
comes – loss of opportunities for physicians to counsel
patients about use of more effective longer term contra-
ceptive methods, but also an increase in price of levonor-
gestrel from 25$ to 45$ 4. However, among women aged
15–44 who have ever had intercourse the fraction who
had ever used ECPs increased from 2% in 2002 to 10% in
2006–2008 (31). Unfortunately, this increase in exposure
has not resulted in positive population impact.Key ques-
tion is how can Croatia benefit from global learning and
secure population impact from the recent emergency
contraceptives introduction.
Learning and recommendations on actionable
points to secure positive EC population impact in
Croatia
EC efficacy: Copper baring IUD is the most effective
emergency contraception, yet it is not easy to secure
product and expertise availability for insertion in emer-
gency settings. If planning EC insertion of copper IUD,
ECPs, preferably ulipristal acetate should be advised to
women. The most effective ECP – ulipristal acetate –
should be recommended to all women seeking EC in line
with SMPC as it significantly reduces risk of unintended
pregnancy compared to levonorgestrel. Levonorgestrel is
the second most effective ECP option, as is significantly
more effective and better tolerated compared to com-
bined oral contraceptives. Combined contraceptives use
in EC should be abandoned in Croatia for its lower effi-
cacy and tolerability. EC availability: For EC to demon-
strate its positive impacts, it is important to ensure mini-
mal delay in EC use from the moment of the unprotected
intercourse. However, potential »over the counter« avail-
ability of levonorgestrel needs to be weighted to the
availability of more effective prescription treatment op-
tion. Structured and close collaboration of physicians
and pharmacists is necessary for EC to demonstrate pop-
ulation impact, therefore a national ECP dispension pro-
tocol is needed to ensure effective women screening, ap-
propriate ECP administration/dispensing and counsel-
ing, but also to ensure structured follow up after ECPs
intake.
Conclusion
It would be relevant to establish current level of EC
awareness / knowledge within general population, how-
ever we should plan our immediate actions assuming it is
low. Continuous emergency contraception awareness cam-
paign should be executed at level of school medicine and
at gynecology care level. Pre-EC counseling should be
provided for every women seeking EC, in order to advise
on importance and possibilities for regular contracep-
tion, but also to clearly underline that ECPs protect only
from previous intercourse, while IUD protects from fu-
ture intercourses only.
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HITNA KONTRACEPCIJA: MO@EMO LI [TO NAU^ITI?
S A @ E T A K
Cilj ovog rada je evaluirati dosada{nje metode hitne kontracepcije (HK) kako bi implementirali dosada{nje ste~eno
znanje i pove}ali udio korisnica HK u Hrvatskoj. Prikazali smo dosada{nja istra`ivanja o razlozima neuspjeha primjene
HK s ciljem detekcije mjera u nacionalnim preporukama za kori{tenje HK. U radu je prikazano {est potencijalnih
razloga neuspjeha HK u postizanju populacijskog u~inka, te ~etiri mogu}e to~ke akcije. To su mala stopa kori{tenja HK
u usporedbi s mogu}im rizi~nim doga|anjima, nizak stupanj znanja o HK u op}oj populaciji, razlike u efikasnosti i
dostupnosti pojedinih metoda HK. S ciljem postizanja ve}eg broja korisnica HK u Hrvatskoj nu`no je zapo~eti s kon-
tinuiranim edukacijskim programima posebice za `ene koje spadaju u rizi~nu skupinu. Preporuke za kori{tenje HK se
moraju temeljiti na boljoj djelotvornosti i sigurnosti preparata, pa se kao primarne opcija za HK preporu~a primjena
materni~kog bakrenog ulo{ka i ulipristal acetata. Savjetovanje je najva`niji korak u osiguranju maksimalne u~inko-
vitosti metoda HK, kao i poticanju budu}eg kori{tenja oralnih hormonskih kontraceptiva. Kona~no, nacionalni algori-
tam za kori{tenje metoda HK trebao bi obuhvatiti u~inkoviti probir `ena, promptnu primjenu HK, te adekvatni »follow
up« korisnica HK.
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